Type  1  diabetes  (T1D)  is  a  chronic  autoimmune  disease  targeting  insulin-  producing  pancreatic beta cells. T1D is a multifactorial disease incorporating genetic and envi-ronmental factors.

Advanced Microbiome Interventions (AMI) start-up has received funding to help it research whether the key to helping type 1 diabetes patients avoid regular insulin shots lies within the body’s microorganisms.

Advanced Microbiome Interventions (AMI) B.V., een startup gevestigd in Amsterdam, heeft een converteerbare lening van €300.000 ontvangen van het Innovatiefonds Noord-Holland.

Amsterdam-based Advanced Microbiome Interventions (AMI), a healthtech startup that develops innovative drugs for type 1 diabetes and other autoimmune diseases, announced that it has received a €300K convertible loan from Innovatiefonds Noord-Holland. 

Type 1 diabetes (T1D) is characterised by islet autoimmunity and beta cell destruction. A gut microbiota-immunological interplay is involved in the pathophysiology of T1D. We studied microbiota-mediated effects on disease progression...

The trillions of commensal microorganisms comprising the gut microbiota have received growing attention owing to their impact on host physiology. Recent advances in our understandings of the host-microbiota crosstalk...

Akkermansia muciniphila is a promising next-generation beneficial microbe due to its natural presence in the mucus layer of the gut, its symbiotic ability to degrade mucus, and its capacity to improve the intestinal barrier function. 

Obesity and type 2 diabetes are associated with low-grade inflammation and specific changes in gut microbiota composition. We previously demonstrated that administration of Akkermansia muciniphila to mice prevents the development of obesity and associated complications.